MCMedicalCodingSoftware
Free trial
XW033FB

XW033FB — Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce Valoct Roxaparv in Periph Vein, Perc, New Tech 11

How XW033FB is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology — What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective — the verb of the procedure
  4. 3Body partThe specific site
  5. 3ApproachHow the site was reached
  6. FDeviceWhat was left in place, if anything
  7. BQualifierA further distinction where one applies

Codes near XW033FB

In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.

  • XW033BAIntroduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033C7Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033CAIntroduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033DAIntroduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033E5Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033F3Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
  • XW033F5Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033FAIntroduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033FBIntroduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW033G5Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033G6Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033H5Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033H6Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033J7Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033K7Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
ICD-10-PCSFY2026